Circulating XXXX cell detection in high-risk non- @entity263 .

@entity5 @entity1 @entity263
PURPOSE: The detection of circulating @entity5 cells (CTCs) provides important prognostic information in @entity1 with @entity263 . We aim to determine the rate of detection of CTCs in @entity1 with high-risk non- @entity263 using the CellSearch(  ) method. METHOD: Samples of peripheral blood (7.5  mL) were drawn from 36 @entity1 with newly diagnosed high-risk non- @entity263 , prior to any initiation of therapy and analyzed for CTCs using the CellSearch(  ) method. RESULTS: The median age was 70  years, median PSA was 14.1, and the median Gleason score was 9. The median 5-year risk of progression of disease using a validated nomogram was 39  %. Five out of 36 @entity1 (14  %, 95  % CI 5-30  %) had CTCs detected in their circulation. Four @entity1 had only 1 CTC per 7.5  mL of blood detected. One @entity1 had 3 CTCs per 7.5  mL of blood detected, which included a circulating @entity5 microemboli. Both on univariate analysis and multivariate analysis, there were no correlations found between CTC positivity and the classic prognostic factors including PSA, Gleason score, T-stage and age. CONCLUSION: This study demonstrates that @entity1 with high-risk, non- @entity263 present infrequently with small number of CTCs in peripheral blood. This finding is consistent with the limited literature available in this setting. Other CTC isolation and detection technologies with improved sensitivity and specificity may enable detection of CTCs with mesenchymal phenotypes, although none as yet have been validated for clinical use. Newer assays are emerging for detection of new putative biomarkers for @entity263 . Correlation of disease control outcomes with CTC detection will be important.
